{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T12:14:48Z","timestamp":1784549688360,"version":"3.55.0"},"reference-count":255,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.cca.2026.121017","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T06:50:48Z","timestamp":1776754248000},"page":"121017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Efficacy of oncolytic viruses (OVs) in malignant tumor therapy: a review on its therapeutic aspects"],"prefix":"10.1016","volume":"589","author":[{"given":"Subham","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himakshi Rekha","family":"Goswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indrani","family":"Barman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nayan","family":"Talukdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2026.121017_bb0005","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0140-6736(25)01635-6","article-title":"The global, regional, and national burden of cancer, 1990\u20132023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023","volume":"406","year":"2025","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.cca.2026.121017_bb0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.43198","article-title":"Global Disparities of Cancer and Its Projected Burden in 2050","volume":"7","author":"Bizuayehu","year":"2024","journal-title":"JAMA Netw. Open"},{"issue":"5","key":"10.1016\/j.cca.2026.121017_bb0015","doi-asserted-by":"crossref","first-page":"oyaf084","DOI":"10.1093\/oncolo\/oyaf084","article-title":"Early onset cancer trends and the persistently higher burden of cancer in young women","volume":"30","author":"Kehm","year":"2025","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.cca.2026.121017_bb0020","first-page":"405","article-title":"Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, 2019","volume":"74","author":"Islami","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.cca.2026.121017_bb0025","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s12672-025-02198-8","article-title":"Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy","volume":"16","author":"Zafar","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.cca.2026.121017_bb0030","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3389\/fmolb.2014.00024","article-title":"Biological response of cancer cells to radiation treatment","volume":"1","author":"Baskar","year":"2014","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.cca.2026.121017_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2022.1610694","article-title":"On-Target Side Effects of Targeted Therapeutics of Cancer","volume":"28","author":"T\u00edm\u00e1r","year":"2022","journal-title":"Pathol. Oncol. Res."},{"issue":"16","key":"10.1016\/j.cca.2026.121017_bb0040","doi-asserted-by":"crossref","first-page":"7724","DOI":"10.3390\/ijms26167724","article-title":"Low antibody dosing in cancer therapy: targeted cytotoxicity combined with anti-tumour immunostimulation","volume":"26","author":"Seledtsov","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cca.2026.121017_bb0045","doi-asserted-by":"crossref","first-page":"5416923","DOI":"10.1155\/2018\/5416923","article-title":"Cancer stem cells (CSCs) in Drug resistance and their therapeutic implications in cancer treatment","volume":"2018","author":"Phi","year":"2018","journal-title":"Stem Cells Int."},{"issue":"3","key":"10.1016\/j.cca.2026.121017_bb0050","first-page":"457","article-title":"Drug resistance mechanisms of cancer stem-like cells and their therapeutic potential as drug targets","volume":"2","author":"Murayama","year":"2019"},{"issue":"17","key":"10.1016\/j.cca.2026.121017_bb0055","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1200\/JCO.2007.15.1829","article-title":"Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis","volume":"26","author":"Eyler","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.cca.2026.121017_bb0060","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/s41392-025-02360-2","article-title":"Cancer stem cells: landscape, challenges and emerging therapeutic innovations","volume":"10","author":"Lee","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"44","key":"10.1016\/j.cca.2026.121017_bb0065","doi-asserted-by":"crossref","first-page":"72322","DOI":"10.18632\/oncotarget.11875","article-title":"Addressing intra-tumoral heterogeneity and therapy resistance","volume":"7","author":"Rybinski","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.cca.2026.121017_bb0070","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.gendis.2022.11.025","article-title":"Cancer cell cycle heterogeneity as a critical determinant of therapeutic resistance","volume":"11","author":"Maleki","year":"2023","journal-title":"Genes Dis."},{"issue":"4","key":"10.1016\/j.cca.2026.121017_bb0075","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","article-title":"Intratumor heterogeneity: the Rosetta Stone of therapy resistance","volume":"37","author":"Marusyk","year":"2020","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.cca.2026.121017_bb0080","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.cca.2026.121017_bb0085","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.3390\/cancers15112912","article-title":"Chemo-immunotherapy: a new trend in cancer treatment","volume":"15","author":"Sordo-Bahamonde","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.cca.2026.121017_bb0090","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/9585614","article-title":"Immunotherapies: exploiting the immune system for cancer treatment","volume":"2018","author":"Koury","year":"2018","journal-title":"J Immunol Res"},{"issue":"154","key":"10.1016\/j.cca.2026.121017_bb0095","first-page":"10","article-title":"The tumor microenvironment and strategies to improve drug distribution","volume":"3","author":"Saggar","year":"2013","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cca.2026.121017_bb0100","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3389\/fphar.2017.00952","article-title":"Modulating the Tumor Microenvironment To Enhance Tumor Nanomedicine Delivery","volume":"8","author":"Zhang","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cca.2026.121017_bb0105","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/805629","article-title":"Systemic delivery of oncolytic viruses: hopes and hurdles","volume":"2012","author":"Ferguson","year":"2012","journal-title":"Adv. Virol."},{"key":"10.1016\/j.cca.2026.121017_bb0110","series-title":"Desk Encyclopedia of General Virology","first-page":"167","article-title":"Oncolytic virus","author":"Casjens","year":"2010"},{"key":"10.1016\/j.cca.2026.121017_bb0115","series-title":"Oncolytic Virus Enables the Immune System to Attack Tumors","author":"Spindler","year":"2023"},{"issue":"1","key":"10.1016\/j.cca.2026.121017_bb0120","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1186\/s12967-023-04360-8","article-title":"Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy","volume":"21","author":"Wang","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.cca.2026.121017_bb0125","series-title":"The Origins of Oncolytic Viral Therapy","author":"Wang","year":"2024"},{"key":"10.1016\/j.cca.2026.121017_bb0130","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.omto.2022.11.002","article-title":"Oncolytic Urabe mumps virus: a promising virotherapy for triple-negative breast cancer","volume":"27","author":"Behrens","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.cca.2026.121017_bb0135","unstructured":"\u201cOncolytic Virus Basis.\u201d Creative Biolabs, www.creative-biolabs.com\/oncolytic-virus\/. (Accessed 08 January, 2026)."},{"issue":"10","key":"10.1016\/j.cca.2026.121017_bb0140","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/cas.13027","article-title":"Oncolytic virus therapy: a new era of cancer treatment at dawn","volume":"107","author":"Fukuhara","year":"2016","journal-title":"Cancer Sci."},{"issue":"3","key":"10.1016\/j.cca.2026.121017_bb0145","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41571-022-00719-w","article-title":"Therapy with oncolytic viruses: progress and challenges","volume":"20","author":"Shalhout","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.cca.2026.121017_bb0150","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejphar.2018.08.042","article-title":"The advent of oncolytic virotherapy in oncology: the Rigvir\u00ae story","volume":"837","author":"Alberts","year":"2018","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.cca.2026.121017_bb0155","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/1568009618666171129221503","article-title":"Oncorine, the world first oncolytic virus medicine and its update in China","volume":"18","author":"Liang","year":"2018","journal-title":"Curr. Cancer Drug Targets"},{"issue":"21","key":"10.1016\/j.cca.2026.121017_bb0160","doi-asserted-by":"crossref","first-page":"5291","DOI":"10.3390\/cancers15215291","article-title":"Clinical advances and future directions of oncolytic virotherapy for head and neck cancer","volume":"15","author":"Wang","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.cca.2026.121017_bb0165","series-title":"Oncolytic Virus Therapy for Cancer: What\u2019s Been Going on in 2025?","author":"Peter","year":"2025"},{"key":"10.1016\/j.cca.2026.121017_bb0170","doi-asserted-by":"crossref","first-page":"1003204","DOI":"10.37349\/ei.2025.1003204","article-title":"The Dual promise of oncolytic viruses: selective targeting and therapeutic enhancement in cancer treatment","volume":"5","author":"Aljabali","year":"2025","journal-title":"Explor. Immunol."},{"issue":"2","key":"10.1016\/j.cca.2026.121017_bb0175","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.3390\/ijms25021180","article-title":"Oncolytic virotherapy: a new paradigm in cancer immunotherapy","volume":"25","author":"Volovat","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.cca.2026.121017_bb0180","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5501\/wjv.v10.i5.229","article-title":"Oncolytic virus therapy in cancer: a current review","volume":"10","author":"Santos Apolonio","year":"2021","journal-title":"World J. Virol."},{"issue":"6","key":"10.1016\/j.cca.2026.121017_bb0185","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.7150\/jca.102285","article-title":"Oncolytic virus therapy in a new era of immunotherapy, enhanced by combination with existing anticancer therapies: turn up the heat!","volume":"16","author":"Fretwell","year":"2025","journal-title":"J. Cancer"},{"issue":"866","key":"10.1016\/j.cca.2026.121017_bb0190","first-page":"26","article-title":"Oncolytic viral therapy and the immune system: a double-edged sword against cancer","volume":"9","author":"Marelli","year":"2018","journal-title":"Front. Immunol."},{"issue":"17","key":"10.1016\/j.cca.2026.121017_bb0195","doi-asserted-by":"crossref","first-page":"10066","DOI":"10.1128\/JVI.02300-13","article-title":"Blockade of type I interferon (IFN) production by retroviral replicating vectors and reduced tumor cell responses to IFN likely contribute to tumor selectivity","volume":"88","author":"Lin","year":"2014","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.cca.2026.121017_bb0200","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2008","article-title":"Defects in interferon pathways as potential biomarkers of sensitivity to oncolytic viruses","volume":"28","author":"Matveeva","year":"2018","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.cca.2026.121017_bb0205","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.semcancer.2021.05.010","article-title":"RAF-MEK-ERK pathway in cancer evolution and treatment","volume":"85","author":"Ullah","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"3","key":"10.1016\/j.cca.2026.121017_bb0210","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1215\/S1152851703000577","article-title":"Poliovirus receptor CD155-targeted oncolysis of glioma","volume":"6","author":"Merrill","year":"2004","journal-title":"Neuro-oncology"},{"key":"10.1016\/j.cca.2026.121017_bb0215","first-page":"1","article-title":"Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances","volume":"5","author":"Simpson","year":"2016","journal-title":"Oncolytic Virother."},{"key":"10.1016\/j.cca.2026.121017_bb0220","series-title":"Nanoparticles as Trojan Horses: A Safe and Effective Way to Deliver Oncolytic Viruses to Treat All Cancers","year":"2023"},{"issue":"4","key":"10.1016\/j.cca.2026.121017_bb0225","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1158\/2326-6066.CIR-14-0015","article-title":"Oncolytic viruses and their application to cancer immunotherapy","volume":"2","author":"Chiocca","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"22","key":"10.1016\/j.cca.2026.121017_bb0230","doi-asserted-by":"crossref","first-page":"e2201734","DOI":"10.1002\/advs.202201734","article-title":"Immunogenic cell death activates the tumor immune microenvironment to boost the immunotherapy efficiency","volume":"9","author":"Li","year":"2022","journal-title":"Adv. Sci."},{"issue":"8","key":"10.1016\/j.cca.2026.121017_bb0235","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.3390\/pharmaceutics14081564","article-title":"An overview on immunogenic cell death in cancer biology and therapy","volume":"14","author":"Rodrigues","year":"2022","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.cca.2026.121017_bb0240","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1002\/1878-0261.12851","article-title":"Targeting immunogenic cell death in cancer","volume":"14","author":"Ahmed","year":"2020","journal-title":"Mol. Oncol."},{"issue":"19-20","key":"10.1016\/j.cca.2026.121017_bb0245","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1089\/hum.2021.140","article-title":"Induction of robust type I interferon levels by oncolytic reovirus requires both viral replication and interferon-\u03b1\/\u03b2 receptor signaling","volume":"32","author":"Oosenbrug","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.cca.2026.121017_bb0250","first-page":"69","article-title":"Reovirus in cancer therapy: an evidence-based review","volume":"3","author":"Clements","year":"2014","journal-title":"Oncolytic Virother."},{"key":"10.1016\/j.cca.2026.121017_bb0255","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.761015","article-title":"Oncolytic viruses and cancer, do you know the main mechanism","volume":"11","author":"Kooti","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.cca.2026.121017_bb0260","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3390\/jcm9010171","article-title":"Oncolytic virotherapy with myxoma virus","volume":"9","author":"Rahman","year":"2020","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.cca.2026.121017_bb0265","first-page":"1","article-title":"Novel therapies in glioblastoma treatment: review of glioblastoma; current treatment options; and novel oncolytic viral therapies","volume":"12","author":"Shah","year":"2023","journal-title":"Med. Sci."},{"issue":"12","key":"10.1016\/j.cca.2026.121017_bb0270","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1586\/14737140.2015.1115725","article-title":"Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy","volume":"15","author":"Harrington","year":"2015","journal-title":"Expert. Rev. Anticancer. Ther."},{"issue":"1","key":"10.1016\/j.cca.2026.121017_bb0275","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12967-023-04817-w","article-title":"Recent advances of engineered oncolytic viruses-based combination therapy for liver cancer","volume":"22","author":"Zhang","year":"2024","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.cca.2026.121017_bb0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40257-016-0238-9","article-title":"Talimogene Laherparepvec (T-VEC) and other oncolytic viruses for the treatment of melanoma","volume":"18","author":"Bommareddy","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.cca.2026.121017_bb0285","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1324744","article-title":"Oncolytic vaccinia virus and cancer immunotherapy","volume":"14","author":"Xu","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.cca.2026.121017_bb0290","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41392-023-01407-6","article-title":"Oncolytic virotherapy: basic principles, recent advances and future directions","volume":"8","author":"Lin","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"15","key":"10.1016\/j.cca.2026.121017_bb0295","doi-asserted-by":"crossref","first-page":"8332","DOI":"10.1128\/JVI.03823-13","article-title":"Faster replication and higher expression levels of viral glycoproteins give the vesicular stomatitis virus\/measles virus hybrid VSV-FH a growth advantage over measles virus","volume":"88","author":"Ayala-Breton","year":"2014","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.cca.2026.121017_bb0300","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s10238-025-01691-2","article-title":"Oncolytic virotherapy and tumor microenvironment modulation","volume":"25","author":"Rivera-Orellana","year":"2025","journal-title":"Clin. Exp. Med."},{"issue":"1","key":"10.1016\/j.cca.2026.121017_bb0305","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003836","article-title":"From scourge to cure: tumour-selective viral pathogenesis as a new strategy against cancer","volume":"10","author":"Ilkow","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.cca.2026.121017_bb0310","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.omtm.2023.03.010","article-title":"Capsid-modified adeno-associated virus vectors as novel vaccine platform for cancer immunotherapy","volume":"29","author":"Franke","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"4","key":"10.1016\/j.cca.2026.121017_bb0315","article-title":"Viral warriors: unlocking the immune system's potential with oncolytic viruses in cancer immunotherapy","volume":"33","author":"Ghavimi","year":"2025","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.cca.2026.121017_bb0320","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/OV.S218494","article-title":"Virus-receptor interactions: structural insights for oncolytic virus development","volume":"8","author":"Jayawardena","year":"2019","journal-title":"Oncolytic Virother."},{"issue":"2","key":"10.1016\/j.cca.2026.121017_bb0325","article-title":"Engineering HSV-1 for oncolytic therapy: from molecular entry mechanisms to retargeting strategies","volume":"13","author":"Zou","year":"2025","journal-title":"Genes Dis."},{"issue":"12","key":"10.1016\/j.cca.2026.121017_bb0330","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1002\/1878-0261.12820","article-title":"Tumors driven by RAS signaling harbor a natural vulnerability to oncolytic virus M1","volume":"14","author":"Cai","year":"2020","journal-title":"Mol. Oncol."},{"issue":"5","key":"10.1016\/j.cca.2026.121017_bb0335","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/cgt.2008.14","article-title":"A cancer terminator virus eradicates both primary and distant human melanomas","volume":"15","author":"Sarkar","year":"2008","journal-title":"Cancer Gene Ther."},{"issue":"7","key":"10.1016\/j.cca.2026.121017_bb0340","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russell","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.cca.2026.121017_bb0345","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jconrel.2015.01.005","article-title":"pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis","volume":"205","author":"Choi","year":"2015","journal-title":"J. Control. Release"},{"issue":"751","key":"10.1016\/j.cca.2026.121017_bb0350","article-title":"Hypoxia-inducible tumour-specific promoters as a dual-targeting transcriptional regulation system for cancer gene therapy","volume":"11","author":"Javan","year":"2017","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.cca.2026.121017_bb0355","series-title":"Essential Human Virology","first-page":"49","article-title":"Virus replication","author":"Louten","year":"2016"},{"issue":"12","key":"10.1016\/j.cca.2026.121017_bb0360","doi-asserted-by":"crossref","first-page":"6015","DOI":"10.1128\/JVI.01537-10","article-title":"Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells","volume":"85","author":"Mansour","year":"2011","journal-title":"J. Virol."},{"issue":"11","key":"10.1016\/j.cca.2026.121017_bb0365","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/s41579-018-0064-6","article-title":"Molecular mechanisms of viral oncogenesis in humans","volume":"16","author":"Krump","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.cca.2026.121017_bb0370","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1618751","article-title":"Viral warfare: unleashing engineered oncolytic viruses to outsmart cancer\u2019s defenses","volume":"16","author":"Omolekan","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cca.2026.121017_bb0375","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/978-1-4939-0888-2_10","article-title":"Cell cycle regulation during viral infection","volume":"1170","author":"Bagga","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.cca.2026.121017_bb0380","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fonc.2014.00167","article-title":"Activated ras signaling pathways and reovirus oncolysis: an update on the mechanism of preferential reovirus replication in cancer cells","volume":"4","author":"Gong","year":"2014","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.cca.2026.121017_bb0385","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: a new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cca.2026.121017_bb0390","series-title":"Oncolytic Virus Therapy: Using Tumor-Targeting Viruses to Treat Cancer","author":"NCI Staff","year":"2018"},{"key":"10.1016\/j.cca.2026.121017_bb0395","series-title":"Oncolytic Viruses: Cancer-Fighting Viruses","year":"2018"},{"key":"10.1016\/j.cca.2026.121017_bb0400","article-title":"The combination therapy of oncolytic virotherapy","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cca.2026.121017_bb0405","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.coi.2021.03.016","article-title":"Modulation of the tumor micro-environment by CD8+ T cell-derived cytokines","volume":"69","author":"Hoekstra","year":"2021","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.cca.2026.121017_bb0410","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1487296","article-title":"From cold to hot: mechanisms of hyperthermia in modulating tumor immunology for enhanced immunotherapy","volume":"16","author":"Abreu","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cca.2026.121017_bb0415","doi-asserted-by":"crossref","first-page":"3145742","DOI":"10.1155\/2017\/3145742","article-title":"Manipulation of Innate and Adaptive Immunity through Cancer Vaccines","volume":"2017","author":"Sayour","year":"2017","journal-title":"J Immunol Res"},{"issue":"2","key":"10.1016\/j.cca.2026.121017_bb0420","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.trecan.2023.09.012","article-title":"Integrating innate and adaptive immunity in oncolytic virus therapy","volume":"10","author":"DePeaux","year":"2024","journal-title":"Trends Cancer"},{"issue":"4","key":"10.1016\/j.cca.2026.121017_bb0425","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1053\/j.seminoncol.2015.05.012","article-title":"Enhancing cancer immunotherapy via activation of innate immunity","volume":"42","author":"Goldberg","year":"2015","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.cca.2026.121017_bb0430","doi-asserted-by":"crossref","first-page":"14754","DOI":"10.1038\/ncomms14754","article-title":"Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy","volume":"8","author":"Liu","year":"2017","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.cca.2026.121017_bb0435","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1596006","article-title":"Oncolytic viruses: how \"lytic\" must they be for therapeutic efficacy?","volume":"8","author":"Davola","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.cca.2026.121017_bb0440","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev-immunol-032712-100008","article-title":"Immunogenic cell death in cancer therapy","volume":"31","author":"Kroemer","year":"2013","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.cca.2026.121017_bb0445","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1476-4598-12-103","article-title":"Oncolytic viruses as therapeutic cancer vaccines","volume":"12","author":"Bartlett","year":"2013","journal-title":"Mol. Cancer"},{"issue":"22","key":"10.1016\/j.cca.2026.121017_bb0450","doi-asserted-by":"crossref","first-page":"8627","DOI":"10.3390\/ijms21228627","article-title":"Oncolytic viruses and immune checkpoint inhibitors: preclinical developments to clinical trials","volume":"21","author":"Hwang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.cca.2026.121017_bb0455","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006780","article-title":"Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer","volume":"11","author":"Jhawar","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.cca.2026.121017_bb0460","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3390\/jcm12031098","article-title":"Talimogene Laherparepvec (T-VEC): a review of the recent advances in cancer therapy","volume":"12","author":"Zhang","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.cca.2026.121017_bb0465","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.940019","article-title":"Herpes simplex virus 1 as an oncolytic viral therapy for refractory cancers","volume":"12","author":"Scanlan","year":"2022","journal-title":"Front. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.cca.2026.121017_bb0470","doi-asserted-by":"crossref","first-page":"TPS4161","DOI":"10.1200\/jco.2013.31.15_suppl.tps4161","volume":"31","author":"Heo","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cca.2026.121017_bb0475","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/978-1-4939-2727-2_19","article-title":"A Phase 2, open-label, randomized study of Pexa-Vec (JX-594) administered by intratumoral injection in patients with unresectable primary Hepatocellular Carcinoma","volume":"1317","author":"Breitbach","year":"2015","journal-title":"Methods Mol. Biol."},{"issue":"7-8","key":"10.1016\/j.cca.2026.121017_bb0480","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41417-019-0129-3","article-title":"Oncolytic activity of HF10 in head and neck squamous cell carcinomas","volume":"27","author":"Esaki","year":"2020","journal-title":"Cancer Gene Ther."},{"issue":"12, suppl","key":"10.1016\/j.cca.2026.121017_bb0485","doi-asserted-by":"crossref","first-page":"9510","DOI":"10.1200\/JCO.2017.35.15_suppl.9510","article-title":"Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma","volume":"35","author":"Andtbacka","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.cca.2026.121017_bb0490","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3390\/cancers10060160","article-title":"A phase II study of Pelareorep (REOLYSIN\u00ae) in combination with gemcitabine for patients with advanced pancreatic adenocarcinoma","volume":"10","author":"Mahalingam","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.cca.2026.121017_bb0495","series-title":"Pelareorep Shows Transformative Survival Data in Advanced Cancers, Pivoting to Registration Studies","author":"Serani","year":"2024"},{"issue":"5","key":"10.1016\/j.cca.2026.121017_bb0500","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.32604\/or.2024.055746","article-title":"Oncolytic adenovirus H101 enhances the anti-tumor effects of PD-1 blockade via CD47 downregulation in tumor cells","volume":"33","author":"Qiao","year":"2025","journal-title":"Oncol. Res."},{"issue":"2","key":"10.1016\/j.cca.2026.121017_bb0505","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2174\/156800907780058817","article-title":"Clinical trials with oncolytic adenovirus in China","volume":"7","author":"Yu","year":"2007","journal-title":"Curr. Cancer Drug Targets"},{"issue":"6","key":"10.1016\/j.cca.2026.121017_bb0515","article-title":"A phase 3, single-arm study of CG0070 in subjects with nonmuscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG)","volume":"40","author":"Uchio","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.cca.2026.121017_bb0520","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent Malignant Glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.cca.2026.121017_bb0525","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1158\/0008-5472.CAN-14-2533","article-title":"Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer","volume":"75","author":"Galanis","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.cca.2026.121017_bb0530","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1483806","article-title":"Oncolytic viruses: a potential breakthrough immunotherapy for multiple myeloma patients","volume":"15","author":"Raimondi","year":"2024","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.cca.2026.121017_bb0535","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/CMR.0000000000000180","article-title":"Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study","volume":"25","author":"Doni\u0146a","year":"2015","journal-title":"Melanoma Res."},{"issue":"4","key":"10.1016\/j.cca.2026.121017_bb0540","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/mt.2011.276","article-title":"The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers","volume":"20","author":"Parato","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cca.2026.121017_bb0545","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fonc.2017.00149","article-title":"genomic signature of the natural oncolytic herpes simplex virus HF10 and its therapeutic role in preclinical and clinical trials","volume":"7","author":"Eissa","year":"2017","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.cca.2026.121017_bb0550","doi-asserted-by":"crossref","first-page":"25","DOI":"10.5662\/wjm.v6.i1.25","article-title":"Clinical development of reovirus for cancer therapy: an oncolytic virus with immune-mediated antitumor activity","volume":"6","author":"Gong","year":"2016","journal-title":"World J. Methodol."},{"issue":"11","key":"10.1016\/j.cca.2026.121017_bb0555","doi-asserted-by":"crossref","first-page":"5767","DOI":"10.3390\/v7112905","article-title":"Oncolytic replication of E1b-deleted adenoviruses","volume":"7","author":"Cheng","year":"2015","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.cca.2026.121017_bb0560","doi-asserted-by":"crossref","first-page":"4119","DOI":"10.1038\/s41467-022-31262-y","article-title":"A phase I\/II study of triple-mutated oncolytic herpes virus G47\u2206 in patients with progressive glioblastoma","volume":"13","author":"Todo","year":"2022","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.cca.2026.121017_bb0565","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1016\/j.juro.2012.07.097","article-title":"A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer","volume":"188","author":"Burke","year":"2012","journal-title":"J. Urol."},{"issue":"1","key":"10.1016\/j.cca.2026.121017_bb0570","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/sj.onc.1203251","article-title":"A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo","volume":"19","author":"Fueyo","year":"2000","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.cca.2026.121017_bb0575","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/sj.clpt.6100409","article-title":"Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide","volume":"82","author":"Myers","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.cca.2026.121017_bb0580","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.7150\/jca.23242","article-title":"Effect of the oncolytic ECHO-7 virus Rigvir\u00ae on the viability of cell lines of human origin in vitro","volume":"9","author":"Tilgase","year":"2018","journal-title":"J. Cancer"},{"key":"10.1016\/j.cca.2026.121017_bb0585","first-page":"83","article-title":"Oncolytic viruses: do they have a role in anti-cancer therapy?","volume":"2","author":"Prestwich","year":"2008","journal-title":"Clin. Med. Oncol."},{"issue":"11","key":"10.1016\/j.cca.2026.121017_bb0590","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.3390\/v15112262","article-title":"Tumor tropism of DNA viruses for oncolytic virotherapy","volume":"15","author":"Enow","year":"2023","journal-title":"Viruses"},{"issue":"1 Pt 1","key":"10.1016\/j.cca.2026.121017_bb0595","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1158\/1078-0432.CCR-1075-3","article-title":"Telomerase-specific replication-selective virotherapy for human cancer","volume":"10","author":"Kawashima","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.cca.2026.121017_bb0600","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1158\/0008-5472.CAN-04-3227","article-title":"An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor","volume":"65","author":"Kambara","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.cca.2026.121017_bb0605","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.omtn.2018.04.003","article-title":"Promoter-operating targeted expression of gene therapy in cancer: current stage and prospect","volume":"11","author":"Chen","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.cca.2026.121017_bb0610","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.831091","article-title":"Genetic modifications that expand oncolytic virus potency","volume":"9","author":"Cristi","year":"2022","journal-title":"Front. Mol. Biosci."},{"issue":"1","key":"10.1016\/j.cca.2026.121017_bb0615","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3390\/v14010118","article-title":"Replication and spread of oncolytic herpes simplex virus in solid tumors","volume":"14","author":"Hong","year":"2022","journal-title":"Viruses"},{"issue":"9","key":"10.1016\/j.cca.2026.121017_bb0620","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02246-18","article-title":"The US11 gene of herpes simplex virus 1 promotes neuroinvasion and periocular replication following corneal infection","volume":"93","author":"Charron","year":"2019","journal-title":"J. Virol."},{"issue":"13","key":"10.1016\/j.cca.2026.121017_bb0625","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1128\/JVI.74.13.6147-6155.2000","article-title":"Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein","volume":"74","author":"Doronin","year":"2000","journal-title":"J. Virol."},{"issue":"9","key":"10.1016\/j.cca.2026.121017_bb0630","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/cgt.2009.12","article-title":"Deletion of the E3-6.7K\/gp19K region reduces the persistence of wild-type adenovirus in a permissive tumor model in Syrian hamsters","volume":"16","author":"Bortolanza","year":"2009","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.cca.2026.121017_bb0635","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.omto.2021.05.007","article-title":"Deletion of immunomodulatory genes as a novel approach to oncolytic vaccinia virus development","volume":"22","author":"Ho","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"issue":"12","key":"10.1016\/j.cca.2026.121017_bb0640","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1158\/1541-7786.MCR-12-0157","article-title":"Reovirus: a targeted therapeutic--progress and potential","volume":"10","author":"Maitra","year":"2012","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.cca.2026.121017_bb0645","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.2147\/OTT.S350136","article-title":"In vitro characterization of enhanced human immune responses by GM-CSF encoding HSV-1-induced melanoma cells","volume":"15","author":"Delic","year":"2022","journal-title":"Onco. Targets Ther."},{"issue":"1","key":"10.1016\/j.cca.2026.121017_bb0650","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40364-021-00294-9","article-title":"The landscape of bispecific T cell engager in cancer treatment","volume":"9","author":"Zhou","year":"2021","journal-title":"Biomark. Res."},{"issue":"8","key":"10.1016\/j.cca.2026.121017_bb0655","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.molmed.2024.05.014","article-title":"Safety of non-replicative and oncolytic replication-selective HSV vectors","volume":"30","author":"Epstein","year":"2024","journal-title":"Trends Mol. Med."},{"issue":"6326","key":"10.1016\/j.cca.2026.121017_bb0660","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/351494a0","article-title":"Adenovirus E1a prevents the retinoblastoma gene product from complexing with a cellular transcription factor","volume":"351","author":"Bandara","year":"1991","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.cca.2026.121017_bb0665","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41564-018-0288-2","article-title":"Vaccinia virus hijacks EGFR signalling to enhance virus spread through rapid and directed infected cell motility","volume":"4","author":"Beerli","year":"2019","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.cca.2026.121017_bb0670","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3389\/fonc.2020.00475","article-title":"Delivery and biosafety of oncolytic virotherapy","volume":"10","author":"Li","year":"2020","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.cca.2026.121017_bb0675","article-title":"Emerging delivery strategy for oncolytic virotherapy","volume":"32","author":"Zhu","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.cca.2026.121017_bb0680","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.omto.2019.10.007","article-title":"Oncolytic viruses for cancer therapy: barriers and recent advances","volume":"15","author":"Zheng","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"issue":"4","key":"10.1016\/j.cca.2026.121017_bb0685","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1172\/JCI122287","article-title":"Oncolytic viruses: overcoming translational challenges","volume":"129","author":"Martinez-Quintanilla","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.cca.2026.121017_bb0695","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3390\/cancers13061383","article-title":"Talimogene laherparepvec (T-VEC): an intralesional cancer immunotherapy for advanced melanoma","volume":"13","author":"Ferrucci","year":"2021","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.cca.2026.121017_bb0700","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2217\/mmt.15.28","article-title":"Intratumoral talimogene laherparepvec therapy in melanoma","volume":"2","author":"Kim","year":"2015","journal-title":"Melanoma Manag."},{"key":"10.1016\/j.cca.2026.121017_bb0705","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/805629","article-title":"Systemic delivery of oncolytic viruses: hopes and hurdles","volume":"2012","author":"Ferguson","year":"2012","journal-title":"Adv. Virol."},{"issue":"14","key":"10.1016\/j.cca.2026.121017_bb0710","doi-asserted-by":"crossref","first-page":"6900","DOI":"10.3390\/ijms26146900","article-title":"Systemic delivery strategies for oncolytic viruses: advancing targeted and efficient tumor therapy","volume":"26","author":"Xia","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cca.2026.121017_bb0715","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3389\/fonc.2020.00421","article-title":"Combination therapy of prostate cancer by oncolytic adenovirus harboring interleukin 24 and ionizing radiation","volume":"10","author":"Mao","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cca.2026.121017_bb0720","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1016\/j.ijbiomac.2021.05.192","article-title":"A review of the tortuous path of nonviral gene delivery and recent progress","volume":"183","author":"Sharma","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.cca.2026.121017_bb0725","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3389\/fonc.2013.00193","article-title":"Strategies to increase drug penetration in solid tumors","volume":"3","author":"Choi","year":"2013","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.cca.2026.121017_bb0730","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13045-025-01717-y","article-title":"Extracellular matrix dynamics in tumor immunoregulation: from tumor microenvironment to immunotherapy","volume":"18","author":"Hu","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.cca.2026.121017_bb0735","first-page":"813","article-title":"Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors","volume":"61","author":"Douglas","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.cca.2026.121017_bb0740","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1473288","article-title":"Oncolytic virotherapy against lung cancer: key receptors and signaling pathways of viral entry","volume":"15","author":"Dong","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cca.2026.121017_bb0745","series-title":"Trojan Horse Bacteria Sneak Cancer-Killing Viruses into Tumors","author":"Columbia University School of Engineering and Applied Science","year":"2025"},{"issue":"4","key":"10.1016\/j.cca.2026.121017_bb0750","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.3390\/pharmaceutics15041257","article-title":"Living cells and cell-derived vesicles: a trojan horse technique for brain delivery","volume":"15","author":"Ou","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.cca.2026.121017_bb0755","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1021\/acsmaterialslett.4c01523","article-title":"Immune cells as trojan horses for cancer nanotherapy","volume":"7","author":"Hermosillo-Abundis","year":"2025","journal-title":"ACS Mater. Lett."},{"issue":"12","key":"10.1016\/j.cca.2026.121017_bb0760","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.20892\/j.issn.2095-3941.2024.0390","article-title":"Improving systemic delivery of oncolytic virus by cellular carriers","volume":"21","author":"Peng","year":"2025","journal-title":"Cancer Biol. Med."},{"issue":"14","key":"10.1016\/j.cca.2026.121017_bb0765","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.3390\/cancers17142296","article-title":"Cell carriers for oncolytic virus delivery: prospects for systemic administration","volume":"17","author":"Sarkisova","year":"2025","journal-title":"Cancers"},{"issue":"22","key":"10.1016\/j.cca.2026.121017_bb0770","doi-asserted-by":"crossref","first-page":"12429","DOI":"10.3390\/ijms222212429","article-title":"Mesenchymal stem cell: a friend or foe in anti-tumor immunity","volume":"22","author":"Harrell","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cca.2026.121017_bb0775","doi-asserted-by":"crossref","first-page":"793","DOI":"10.18632\/oncotarget.28672","article-title":"Mesenchymal stem cells - the secret agents of cancer immunotherapy: promises, challenges, and surprising twists","volume":"15","author":"Minev","year":"2024","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.cca.2026.121017_bb0785","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/gt.2012.31","article-title":"Using clinically approved cyclophosphamide regimens to control the humoral immune response to oncolytic viruses","volume":"20","author":"Peng","year":"2013","journal-title":"Gene Ther."},{"issue":"13","key":"10.1016\/j.cca.2026.121017_bb0790","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1089\/hum.1996.7.13-1555","article-title":"Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung","volume":"7","author":"Jooss","year":"1996","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.cca.2026.121017_bb0795","unstructured":"Aerts Kaya, Fatima S. F., et al. Immune Modulation in Gene Therapy Studies: Points to Consider for Environmental Risk Assessment. Erasmus Medical Center, 2010. Erasmus University Repository, hdl.handle.net\/1765\/21967."},{"issue":"2","key":"10.1016\/j.cca.2026.121017_bb0800","doi-asserted-by":"crossref","first-page":"468","DOI":"10.3390\/v2020468","article-title":"PEGylated adenoviruses: from mice to monkeys","volume":"2","author":"Wonganan","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.cca.2026.121017_bb0805","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3389\/fcell.2020.00376","article-title":"Cloaked viruses and viral factors in cutting edge exosome-based therapies","volume":"8","author":"Dogrammatzis","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"issue":"46","key":"10.1016\/j.cca.2026.121017_bb0810","doi-asserted-by":"crossref","first-page":"39953","DOI":"10.1021\/acsami.7b09931","article-title":"Targeting and enrichment of viral pathogen by cell membrane cloaked magnetic nanoparticles for enhanced detection","volume":"9","author":"Chen","year":"2017","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.cca.2026.121017_bb0815","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113822","article-title":"Formulation-optimized oncolytic viruses: advancing systemic delivery and immune amplification","volume":"383","author":"Ma","year":"2025","journal-title":"J. Control. Release"},{"issue":"6","key":"10.1016\/j.cca.2026.121017_bb0820","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s40259-025-00743-z","article-title":"Oncolytic virotherapy in solid tumors: a current review","volume":"39","author":"Chen","year":"2025","journal-title":"BioDrugs"},{"issue":"5","key":"10.1016\/j.cca.2026.121017_bb0825","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41419-024-06697-4","article-title":"Modulating extracellular matrix stiffness: a strategic approach to boost cancer immunotherapy","volume":"15","author":"Mai","year":"2024","journal-title":"Cell Death Dis."},{"issue":"11","key":"10.1016\/j.cca.2026.121017_bb0830","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.3390\/cancers12113219","article-title":"Past, present and future of oncolytic reovirus","volume":"12","author":"M\u00fcller","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.cca.2026.121017_bb0835","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3390\/curroncol28010019","article-title":"Oncolytic viruses and hematological malignancies: a new class of immunotherapy drugs","volume":"28","author":"Innao","year":"2020","journal-title":"Curr. Oncol."},{"issue":"8","key":"10.1016\/j.cca.2026.121017_bb0840","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3390\/biomedicines10082024","article-title":"Tumor temperature: friend or foe of virus-based cancer immunotherapy","volume":"10","author":"Knapp","year":"2022","journal-title":"Biomedicines"},{"issue":"6","key":"10.1016\/j.cca.2026.121017_bb0845","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.3390\/cimb45060307","article-title":"Adenovirus as a vector and oncolytic virus","volume":"45","author":"Matsunaga","year":"2023","journal-title":"Curr. Issues Mol. Biol."},{"issue":"10","key":"10.1016\/j.cca.2026.121017_bb0850","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/s41417-022-00469-y","article-title":"Challenges and progress toward tumor-targeted therapy by systemic delivery of polymer-complexed oncolytic adenoviruses","volume":"29","author":"Thambi","year":"2022","journal-title":"Cancer Gene Ther."},{"issue":"3","key":"10.1016\/j.cca.2026.121017_bb0855","doi-asserted-by":"crossref","first-page":"208","DOI":"10.4161\/cam.2.3.6353","article-title":"\"Armed\" oncolytic herpes simplex viruses for brain tumor therapy","volume":"2","author":"Todo","year":"2008","journal-title":"Cell Adhes. Migr."},{"issue":"4","key":"10.1016\/j.cca.2026.121017_bb0860","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.3390\/ijms24043681","article-title":"The dilemma of HSV-1 oncolytic virus delivery: the method choice and hurdles","volume":"24","author":"Tang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.cca.2026.121017_bb0865","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.3390\/cancers12123514","article-title":"HSV-1 oncolytic viruses from bench to bedside: an overview of current clinical trials","volume":"12","author":"Koch","year":"2020","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.cca.2026.121017_bb0870","first-page":"359","article-title":"Vaccinia virus and oncolytic virotherapy of cancer","volume":"7","author":"Thorne","year":"2005","journal-title":"Curr. Opin. Mol. Ther."},{"issue":"7","key":"10.1016\/j.cca.2026.121017_bb0875","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1158\/0008-5472.CAN-07-6515","article-title":"Enhancing poxvirus oncolytic effects through increased spread and immune evasion","volume":"68","author":"Kirn","year":"2008","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.cca.2026.121017_bb0880","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.3390\/vaccines10091552","article-title":"Design strategies and precautions for using vaccinia virus in tumor virotherapy","volume":"10","author":"Liu","year":"2022","journal-title":"Vaccines"},{"issue":"3","key":"10.1016\/j.cca.2026.121017_bb0885","doi-asserted-by":"crossref","first-page":"27","DOI":"10.53964\/id.2024027","article-title":"Oncolytic viruses: from basics to challenges to innovation","volume":"1","author":"Haidar","year":"2024","journal-title":"Innov. Discov."},{"key":"10.1016\/j.cca.2026.121017_bb0890","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/978-1-4939-9794-7_14","article-title":"Delivery of oncolytic reovirus by cell carriers","volume":"2058","author":"Ilett","year":"2020","journal-title":"Methods Mol. Biol."},{"issue":"1","key":"10.1016\/j.cca.2026.121017_bb0895","doi-asserted-by":"crossref","first-page":"e1115641","DOI":"10.1080\/2162402X.2015.1115641","article-title":"First oncolytic virus approved for melanoma immunotherapy","volume":"5","author":"Pol","year":"2015","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.cca.2026.121017_bb0900","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102239","article-title":"The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma: an open-label, single-arm, pilot study","volume":"9","author":"Yi","year":"2024","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.cca.2026.121017_bb0905","doi-asserted-by":"crossref","first-page":"16","DOI":"10.21037\/cco.2018.04.04","article-title":"The emerging role of oncolytic virus therapy against cancer","volume":"7","author":"Russell","year":"2018","journal-title":"Chin. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.cca.2026.121017_bb0910","doi-asserted-by":"crossref","first-page":"878","DOI":"10.3390\/cimb47110878","article-title":"Recombinant oncolytic viruses: hexagonal warriors in the field of solid tumor immunotherapy","volume":"47","author":"Zhang","year":"2025","journal-title":"Curr. Issues Mol. Biol."},{"issue":"6","key":"10.1016\/j.cca.2026.121017_bb0915","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/1750743X.2025.2501926","article-title":"Oncolytic reovirus enhances the effect of CEA immunotherapy when combined with PD1-PDL1 inhibitor in a colorectal cancer model","volume":"17","author":"Yari","year":"2025","journal-title":"Immunotherapy"},{"issue":"2","key":"10.1016\/j.cca.2026.121017_bb0925","first-page":"25","article-title":"Advancements on the synergistic application of oncolytic viruses and molecularly targeted therapies for the treatment of solid tumors (Review)","volume":"68","author":"Bi","year":"2026","journal-title":"Int. J. Oncol."},{"issue":"1","key":"10.1016\/j.cca.2026.121017_bb0930","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12935-021-02407-8","article-title":"Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier","volume":"22","author":"Vafaei","year":"2022","journal-title":"Cancer Cell Int."},{"issue":"8","key":"10.1016\/j.cca.2026.121017_bb0935","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/oncolo\/oyad041","article-title":"Regulatory issues: PMDA - review of Sakigake designation products: oncolytic virus therapy with delytact injection (Teserpaturev) for Malignant Glioma","volume":"28","author":"Maruyama","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.cca.2026.121017_bb0940","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/OV.S100072","article-title":"Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma","volume":"6","author":"Babiker","year":"2017","journal-title":"Oncolytic Virother."},{"key":"10.1016\/j.cca.2026.121017_bb0945","doi-asserted-by":"crossref","unstructured":"Tessarollo, Nayara Gusm\u00e3o et al. \u201cNonreplicating adenoviral vectors: improving tropism and delivery of cancer gene therapy.\u201d Cancers vol. 13,8 1863. 2021, doi:10.3390\/cancers13081863.","DOI":"10.3390\/cancers13081863"},{"key":"10.1016\/j.cca.2026.121017_bb0950","article-title":"Synergy of oncolytic adenovirus and immune checkpoint inhibitors: transforming cancer immunotherapy paradigms","volume":"16","author":"Cheng","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cca.2026.121017_bb0955","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/OV.S59640","article-title":"The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594)","volume":"4","author":"Breitbach","year":"2015","journal-title":"Oncolytic Virother."},{"issue":"9","key":"10.1016\/j.cca.2026.121017_bb0960","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1038\/mt.2015.109","article-title":"Phase 1b trial of biweekly intravenous Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus in colorectal cancer","volume":"23","author":"Park","year":"2015","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.cca.2026.121017_bb0965","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.4161\/hv.29594","article-title":"Pre-existing immunity against Ad vectors: humoral, cellular, and innate response, what\u2019s important?","volume":"10","author":"Fausther-Bovendo","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"issue":"5","key":"10.1016\/j.cca.2026.121017_bb0970","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004167","article-title":"Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment","volume":"10","author":"Wang","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.cca.2026.121017_bb0975","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103362","article-title":"Comparative safety and efficacy of oncolytic virotherapy for the treatment of individuals with malignancies: a systematic review, meta-analysis, and Bayesian network meta-analysis","volume":"86","author":"Lau","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.cca.2026.121017_bb0980","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1308890","article-title":"Oncolytic virotherapy in cancer treatment: challenges and optimization prospects","volume":"14","author":"Chen","year":"2023","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.cca.2026.121017_bb0985","article-title":"Oncolytic viruses for the treatment of cancer (a review)","volume":"2","author":"Ramesh","year":"2009","journal-title":"Biomed. Pharmacol. J."},{"key":"10.1016\/j.cca.2026.121017_bb0990","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3389\/fonc.2017.00153","article-title":"Combining oncolytic adenovirus with radiation-a paradigm for the future of radiosensitization","volume":"7","author":"O\u2019Cathail","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.cca.2026.121017_bb0995","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1344272","article-title":"Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors","volume":"15","author":"Ouyang","year":"2024","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.cca.2026.121017_bb1000","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.32604\/or.2025.067824","article-title":"Immune checkpoint inhibitors combined with oncolytic virotherapy: synergy, heterogeneity, and safety in cancer treatment","volume":"33","author":"Feng","year":"2025","journal-title":"Oncol. Res."},{"issue":"2","key":"10.1016\/j.cca.2026.121017_bb1005","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/mt.2009.283","article-title":"Intelligent design: combination therapy with oncolytic viruses","volume":"18","author":"Ottolino-Perry","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cca.2026.121017_bb1010","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2025.1641267","article-title":"Oncolytic viruses in head and neck cancers: clinical applications and therapeutic potential","volume":"16","author":"Gupta","year":"2025","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.cca.2026.121017_bb1015","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3389\/fonc.2014.00145","article-title":"Chemotherapy and oncolytic virotherapy: advanced tactics in the war against cancer","volume":"4","author":"Nguyen","year":"2014","journal-title":"Front. Oncol."},{"issue":"17","key":"10.1016\/j.cca.2026.121017_bb1020","article-title":"Combining oncolytic virus and radiation therapy for cancer management","volume":"8","author":"Jayalie","year":"2022","journal-title":"J. Cancer Metastasis Treat."},{"key":"10.1016\/j.cca.2026.121017_bb1025","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103362","article-title":"Comparative safety and efficacy of oncolytic virotherapy for the treatment of individuals with malignancies: a systematic review, meta-analysis, and Bayesian network meta-analysis","volume":"86","author":"Lau","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.cca.2026.121017_bb1030","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1007\/s12672-025-03973-3","article-title":"A comprehensive review redefining viruses as therapeutic agents in cancer treatment","volume":"16","author":"Jadhav","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.cca.2026.121017_bb1035","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1178382","article-title":"Biosafety and biohazard considerations of HSV-1-based oncolytic viral immunotherapy","volume":"10","author":"Robilotti","year":"2023","journal-title":"Front. Mol. Biosci."},{"issue":"19","key":"10.1016\/j.cca.2026.121017_bb1040","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.3390\/vaccines11091448","article-title":"Oncolytic viruses: an inventory of shedding data from clinical trials and elements for the environmental risk assessment","volume":"11","author":"Onnockx","year":"2023","journal-title":"Vaccines"},{"key":"10.1016\/j.cca.2026.121017_bb1045","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.omtm.2020.01.001","article-title":"Oncolytic viruses and the immune system: the dynamic duo","volume":"17","author":"Lemos de Matos","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"51","key":"10.1016\/j.cca.2026.121017_bb1050","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1016\/j.vaccine.2016.04.060","article-title":"Unique safety issues associated with virus-vectored vaccines: potential for and theoretical consequences of recombination with wild type virus strains","volume":"34","author":"Condit","year":"2016","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.cca.2026.121017_bb1055","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1080\/21645515.2015.1037058","article-title":"Oncolytic viruses: from bench to bedside with a focus on safety","volume":"11","author":"Buijs","year":"2015","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.cca.2026.121017_bb1060","author":"European Medicines Agency"},{"issue":"1","key":"10.1016\/j.cca.2026.121017_bb1070","doi-asserted-by":"crossref","first-page":"27209","DOI":"10.1038\/s41598-024-78313-6","article-title":"Murine colon cancer derived cells exhibit heterogeneous resistance profiles against an oncolytic virus","volume":"14","author":"Larrieux","year":"2024","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.cca.2026.121017_bb1075","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3892\/ijmm.2025.5612","article-title":"Resistance to oncolytic virotherapy: multidimensional mechanisms and therapeutic breakthroughs (Review)","volume":"56","author":"Xu","year":"2025","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.cca.2026.121017_bb1085","doi-asserted-by":"crossref","first-page":"e29528","DOI":"10.4161\/tisb.29528","article-title":"Barriers to drug delivery in solid tumors","volume":"2","author":"Sriraman","year":"2014","journal-title":"Tissue Barriers"},{"key":"10.1016\/j.cca.2026.121017_bb1090","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/OV.S145262","article-title":"Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect","volume":"6","author":"Yokoda","year":"2017","journal-title":"Oncolytic Virother."},{"issue":"1","key":"10.1016\/j.cca.2026.121017_bb1095","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s004180000224","article-title":"Tumor structure and extracellular matrix as a possible barrier for therapeutic approaches using immune cells or adenoviruses in colorectal cancer","volume":"115","author":"Kuppen","year":"2001","journal-title":"Histochem. Cell Biol."},{"issue":"11","key":"10.1016\/j.cca.2026.121017_bb1100","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nrclinonc.2010.139","article-title":"Delivering nanomedicine to solid tumors","volume":"7","author":"Jain","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.cca.2026.121017_bb1105","first-page":"11","article-title":"Heterogeneous delivery is a barrier to the translational advancement of oncolytic virotherapy for treating solid tumors","volume":"6","author":"Miller","year":"2014","journal-title":"Virus Adapt. Treat."},{"key":"10.1016\/j.cca.2026.121017_bb1110","doi-asserted-by":"crossref","DOI":"10.2217\/fon-2022-0440","article-title":"Oncolytic viruses: challenges and considerations in an evolving clinical landscape","author":"Lauer","year":"2022","journal-title":"Future Oncol."},{"issue":"4","key":"10.1016\/j.cca.2026.121017_bb1120","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ymthe.2018.01.019","article-title":"Pre-existing immunity to oncolytic virus potentiates its immunotherapeutic efficacy","volume":"26","author":"Ricca","year":"2018","journal-title":"Mol. Ther."},{"issue":"R1","key":"10.1016\/j.cca.2026.121017_bb1125","doi-asserted-by":"crossref","first-page":"R42","DOI":"10.1093\/hmg\/ddv451","article-title":"Progress and challenges in viral vector manufacturing","volume":"25","author":"van der Loo","year":"2016","journal-title":"Hum. Mol. Genet."},{"issue":"7","key":"10.1016\/j.cca.2026.121017_bb1135","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1016\/j.xphs.2021.03.024","article-title":"Manufacturing challenges and rational formulation development for AAV viral vectors","volume":"110","author":"Srivastava","year":"2021","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.cca.2026.121017_bb1140","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s10238-025-01691-2","article-title":"Oncolytic virotherapy and tumor microenvironment modulation","volume":"25","author":"Rivera-Orellana","year":"2025","journal-title":"Clin. Exp. Med."},{"issue":"8_Supplement","key":"10.1016\/j.cca.2026.121017_bb1145","first-page":"953","article-title":"Abstract 953: Oncolytic viruses as in situ personalized tumor vaccines for durable efficacy","volume":"85","author":"Guo","year":"2025","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.cca.2026.121017_bb1150","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3390\/cancers13040614","article-title":"Personalizing oncolytic virotherapy for glioblastoma: in search of biomarkers for response","volume":"13","author":"Stavrakaki","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.cca.2026.121017_bb1155","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1038\/s41467-021-22929-z","article-title":"Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination","volume":"12","author":"Roy","year":"2021","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.cca.2026.121017_bb1160","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ccell.2018.03.011","article-title":"Oncolytic viruses as antigen-agnostic cancer vaccines","volume":"33","author":"Russell","year":"2018","journal-title":"Cancer Cell"},{"issue":"24","key":"10.1016\/j.cca.2026.121017_bb1165","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.3390\/cancers14246136","article-title":"Development of allogeneic stem cell-based platform for delivery and potentiation of oncolytic virotherapy","volume":"14","author":"Nguyen","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.cca.2026.121017_bb1170","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12967-019-1829-z","article-title":"Delivery of oncolytic vaccinia virus by matched allogeneic stem cells overcomes critical innate and adaptive immune barriers","volume":"17","author":"Draganov","year":"2019","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.cca.2026.121017_bb1185","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.3389\/fimmu.2019.01848","article-title":"Immune conversion of tumor microenvironment by oncolytic viruses: the protoparvovirus H-1PV case study","volume":"10","author":"Marchini","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cca.2026.121017_bb1190","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1535647","article-title":"Extracellular matrix re-normalization to improve cold tumor penetration by oncolytic viruses","volume":"15","author":"Soko","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cca.2026.121017_bb1195","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.omto.2019.10.002","article-title":"Dual-isotope SPECT imaging with NIS reporter gene and duramycin to visualize tumor susceptibility to oncolytic virus infection","volume":"15","author":"Zhang","year":"2019","journal-title":"Mol. Ther. Oncolytics"},{"issue":"1","key":"10.1016\/j.cca.2026.121017_bb1200","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1517\/14712598.2016.1100162","article-title":"The use of the NIS reporter gene for optimizing oncolytic virotherapy","volume":"16","author":"Miller","year":"2016","journal-title":"Expert. Opin. Biol. Ther."},{"issue":"11","key":"10.1016\/j.cca.2026.121017_bb1205","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.3390\/cancers17111854","article-title":"Oncolytic viruses as a novel therapeutic approach for colorectal cancer: mechanisms, current advances, and future directions","volume":"17","author":"P\u00e9rez-Dom\u00ednguez","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.cca.2026.121017_bb1210","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.790150","article-title":"Oncolytic virotherapy: from bench to bedside","volume":"9","author":"Yang","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.cca.2026.121017_bb1215","series-title":"Oncolytic Virus Cancer Therapy: Transforming Cancer Treatment","author":"DelveInsight","year":"2024"},{"key":"10.1016\/j.cca.2026.121017_bb1220","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.omto.2020.03.003","article-title":"Comparison of clinically relevant oncolytic virus platforms for enhancing T cell therapy of solid tumors","volume":"17","author":"Cervera-Carrascon","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"issue":"5","key":"10.1016\/j.cca.2026.121017_bb1225","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3390\/vaccines13050524","article-title":"Past, present, and future of viral vector vaccine platforms: a comprehensive review","volume":"13","author":"Tang","year":"2025","journal-title":"Vaccines"},{"issue":"2","key":"10.1016\/j.cca.2026.121017_bb1230","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3390\/v10020090","article-title":"Oncotargeting by vesicular stomatitis virus (VSV): advances in cancer therapy","volume":"10","author":"Bishnoi","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.cca.2026.121017_bb1235","first-page":"157","article-title":"Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy","volume":"4","author":"Simovic","year":"2015","journal-title":"Oncolytic Virother."},{"issue":"12","key":"10.1016\/j.cca.2026.121017_bb1240","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1038\/leu.2017.120","article-title":"Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma","volume":"31","author":"Dispenzieri","year":"2017","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.cca.2026.121017_bb1245","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1038\/s41375-020-0828-7","article-title":"Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma","volume":"34","author":"Packiriswamy","year":"2020","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.cca.2026.121017_bb1250","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/neuonc\/noad052","article-title":"Polio virotherapy targets the malignant glioma myeloid infiltrate with diffuse microglia activation engulfing the CNS","volume":"25","author":"Yang","year":"2023","journal-title":"Neuro-oncology"},{"issue":"3","key":"10.1016\/j.cca.2026.121017_bb1255","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2217\/fmb.12.4","article-title":"Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions","volume":"7","author":"Zamarin","year":"2012","journal-title":"Future Microbiol."},{"key":"10.1016\/j.cca.2026.121017_bb1260","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2022.930207","article-title":"Evolving role of seneca valley virus and its biomarker TEM8\/ANTXR1 in cancer therapeutics","volume":"9","author":"Corbett","year":"2022","journal-title":"Front. Mol. Biosci."},{"issue":"5","key":"10.1016\/j.cca.2026.121017_bb1265","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3390\/biomedicines9050548","article-title":"Combination of mesenchymal stem cell-delivered oncolytic virus with prodrug activation increases efficacy and safety of colorectal cancer therapy","volume":"9","author":"Ho","year":"2021","journal-title":"Biomedicines"},{"issue":"3-4","key":"10.1016\/j.cca.2026.121017_bb1270","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1089\/hum.2020.278","article-title":"Combining oncolytic viruses with chimeric antigen receptor T cell therapy","volume":"32","author":"McGrath","year":"2021","journal-title":"Hum. Gene Ther."},{"issue":"5","key":"10.1016\/j.cca.2026.121017_bb1275","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1007\/s00253-015-7267-9","article-title":"Bioreactors for high cell density and continuous multi-stage cultivations: options for process intensification in cell culture-based viral vaccine production","volume":"100","author":"Tapia","year":"2016","journal-title":"Appl. Microbiol. Biotechnol."},{"issue":"1","key":"10.1016\/j.cca.2026.121017_bb1280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2478\/raon-2022-0002","article-title":"Cancer gene therapy goes viral: viral vector platforms come of age","volume":"56","author":"Bezeljak","year":"2022","journal-title":"Radiol. Oncol."},{"issue":"8","key":"10.1016\/j.cca.2026.121017_bb0510","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41591-022-01897-x","article-title":"Intratumoral oncolytic herpes virus G47\u2206 for residual or recurrent glioblastoma: a phase 2 trial","volume":"28","author":"Todo","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.cca.2026.121017_bb0690","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1479483","article-title":"Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer","volume":"15","author":"Skalickova","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cca.2026.121017_bb0780","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3389\/fonc.2017.00106","article-title":"Immune system, friend or foe of oncolytic virotherapy?","volume":"7","author":"Filley","year":"2017","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.cca.2026.121017_bb0920","first-page":"4192","article-title":"Advances in the clinical development of oncolytic viruses","volume":"14","author":"Li","year":"2022","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.cca.2026.121017_bb1065","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1724768","article-title":"Opportunities, challenges, and future perspectives of oncolytic virus therapy for malignant melanoma","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.cca.2026.121017_bb1080","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.3390\/vaccines9101166","article-title":"Resistance mechanisms influencing oncolytic virotherapy, a systematic analysis","volume":"9","author":"Bhatt","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.cca.2026.121017_bb1115","doi-asserted-by":"crossref","first-page":"6587258","DOI":"10.1155\/2017\/6587258","article-title":"The role of the innate immune system in oncolytic virotherapy","volume":"2017","author":"Phan","year":"2017","journal-title":"Comput. Math. Methods Med."},{"issue":"3","key":"10.1016\/j.cca.2026.121017_bb1130","first-page":"34","article-title":"Viral vector process development and manufacturing","volume":"27","author":"Dream","year":"2024","journal-title":"Am. Pharm. Rev."},{"issue":"1","key":"10.1016\/j.cca.2026.121017_bb1175","article-title":"TheraVision: engineering platform technology for the development of oncolytic viruses based on herpes simplex virus type 1","volume":"32","author":"Funk","year":"2024","journal-title":"Mol. Ther. Oncol."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126001993?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898126001993?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:19:05Z","timestamp":1781511545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898126001993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":255,"alternative-id":["S0009898126001993"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2026.121017","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of oncolytic viruses (OVs) in malignant tumor therapy: a review on its therapeutic aspects","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2026.121017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"121017"}}